Age-related testosterone decline is due to waning of both testicular and hypothalamic-pituitary function

Area of Science:

• Endocrinology
• Andrology
• Geriatrics

Background:

• Hypogonadism is characterized by inadequate endogenous testosterone secretion, leading to levels below the normal range.
• Age-related hypogonadism results from a combination of primary testicular failure and secondary hypothalamic-pituitary axis dysfunction.
• This condition can manifest through various clinical signs and symptoms.

Purpose of the Study:

• To elucidate the mechanisms underlying multifactorial acquired androgen deficiency in aging males.
• To review the current scientific literature and clinical evidence regarding testosterone replacement therapy (TRT) in this demographic.
• To highlight the ongoing controversies and considerations surrounding TRT for aging men.

Main Methods:

• Literature review of scientific articles and clinical studies.
• Analysis of mechanisms contributing to age-related hypogonadism.
• Examination of data on the efficacy and safety of testosterone replacement therapy.

Main Results:

• Age-related hypogonadism is multifactorial, involving both testicular and hypothalamic-pituitary factors.
• Evidence regarding the benefits and risks of testosterone replacement therapy in aging males is debated.
• Understanding the complex etiology is crucial for managing androgen deficiency.

Conclusions:

• Hypogonadism in aging men is a complex endocrine condition with diverse underlying causes.
• The decision to initiate testosterone replacement therapy requires careful consideration of the available evidence and patient-specific factors.
• Further research is needed to clarify the long-term outcomes and optimal use of TRT in older men.